Compare Ginkgo Bioworks Holdings Inc (DNA) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Vanguard International High Dividend Yield ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.65 (market cap $763.64M), while Vanguard International High Dividend Yield ETF trades at $100.3 (market cap $22.80B). The key difference: Vanguard International High Dividend Yield ETF is far larger — about 29.9× Ginkgo Bioworks Holdings Inc's market cap, and Vanguard International High Dividend Yield ETF is more actively traded (748,441 versus 3,204,177). Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Vanguard International High Dividend Yield ETF for 50 Days on average.
| DNA | VYMI | |
|---|---|---|
Market Cap | $763.64M | $22.80B |
Volume | 3,204,177 | 748,441 |
Sector | Health | Broad Market / Factor |
52-Week High | $15.83 | $107.13 |
52-Week Low | $5.48 | $82.92 |
Typical Hold Time | 7 Days | 50 Days |
Enterprise Value | $865.59M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.
Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.
VYMI trades at $100.27 with minimal daily movement (+0.04%). Technical indicators show a bearish trend with moving averages signaling caution, though oscillators are neutral. Recent news highlights institutional accumulation and positive performance comparisons to peers. The ETF's international high-dividend strategy focuses on financials, energy, and healthcare sectors.
Outlook remains mixed: bullish sentiment from media and institutional inflows contrasts with bearish technicals. Key opportunities include sector alignment with rising rates and attractive yield; risks involve global economic volatility and concentrated financial exposure. Investors should weigh dividend stability against technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
